Loading clinical trials...

Efficacy and Safety of the Hcoil Deep TMS for the Treatment of Cannabis Addiction | Clinical Trials | Clareo Health

UNKNOWNPHASE1/PHASE2

Efficacy and Safety of the Hcoil Deep TMS for the Treatment of Cannabis Addiction

NCT00543036•Shalvata Mental Health Center

Summary

Evaluation of efficacy and safety of H-coil deep transcranial magnetic stimulation 9 week treatment trial for cannabis addiction as assessed by measures of drug intake and craving.

Eligibility

Age

21 - 70 years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Male and Female, aged 21-70 years, who meet DSM-IV TR diagnostic criteria for cannabis abuse and are motivated to quit cannabis use as assessed in the screening visit and gave their written informed consent to participate in the study.

Exclusion Criteria

•History of a primary major psychiatric other then cannabis abuse, or cognitive disorder according to DSM-IV TR criteria.
•Hamilton depression scale rated 25 and above (moderate to severe depression)
•Current alcohol or other substance abuse or dependence
•Alcohol or other substance abuse or dependence during the last 12 months before recruitment.
•History of or evidence of significant brain malformation,neoplasm, head injury, cerebral vascular events,neurodegenerative disorder or brain surgery.
•Severe somatic co-morbidity
•History of seizures Cardiac pace maker or other electronic implants Pregnancy and lactation

Locations (1)

Shalvata Mental Health Center

Hod HaSharon, Israel

Key Dates

Last Updated

October 12, 2007

Conditions

Marijuana Abuse

Interventions

H-Coil deep TMS

DEVICE

Contacts

Ziv Carmel, M.D.

CONTACT

+972-9-7478570 zivca@clalit.org.il

Effect of AEF0117 on Treatment-seeking Patients With Cannabis Use Disorder (CUD)

NCT05322941

Marijuana Abuse

View study

COMPLETEDNA

Substance Use Interventions for Truant Adolescents

NCT03655574

Adolescent Problem BehaviorTruancy; Unsocialized+4 more

View study

COMPLETED

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: October 12, 2007Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Efficacy and Safety of the Hcoil Deep TMS for the Treatment of Cannabis Addiction

Inclusion Criteria

Exclusion Criteria

Effect of AEF0117 on Treatment-seeking Patients With Cannabis Use Disorder (CUD)

Substance Use Interventions for Truant Adolescents

Effect of AEF0117 on Subjective Effects of Cannabis in CUD Subjects

Therapeutic Substance Abuse Treatment in Pregnancy - 1

Mobile Contingency Management for Marijuana and Tobacco Cessation

Free Venlafaxine Treatment for Marijuana Addiction and Depression - 1